Scarica l'app Stockscreener
0.6118
1.29%
-0.0082
Precedente Chiudi:
$0.62
Aprire:
$0.6014
Volume 24 ore:
55,090
Relative Volume:
0.44
Capitalizzazione di mercato:
$34.11M
Reddito:
$76.19M
Utile/perdita netta:
$-1.61M
Rapporto P/E:
61.18
EPS:
0.01
Flusso di cassa netto:
$28.98M
1 W Prestazione:
+0.33%
1M Prestazione:
+2.00%
6M Prestazione:
-53.64%
1 anno Prestazione:
-62.68%
Intervallo 1D:
$0.6002
$0.64
Intervallo di 1 settimana:
$0.57
$0.6421
Portata 52W:
$0.5052
$1.69
Spero Therapeutics Inc Stock (SPRO) Company Profile
Nome
Spero Therapeutics Inc
Settore
Industria
Telefono
857-242-1600
Indirizzo
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Confronta SPRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
0.612 | 34.11M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.94 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.99 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
557.65 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
263.85 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
227.79 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Iniziato | Evercore ISI | Outperform |
| 2019-11-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-09-09 | Iniziato | Janney | Buy |
| 2018-02-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Iniziato | BofA/Merrill | Neutral |
| 2017-11-27 | Iniziato | Oppenheimer | Outperform |
| 2017-11-27 | Iniziato | Stifel | Buy |
Mostra tutto
Spero Therapeutics Inc Borsa (SPRO) Ultime notizie
Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times
Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune
Spero Therapeutics Confirms Q1 Earnings Date: Latest Updates on Rare Disease and MDR Programs Coming May 13 - Stock Titan
Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz
New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus
Spero Therapeutics appoints new CEO and board nominee - Investing.com
Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire
Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener
Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: - GuruFocus
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa
Spero Therapeutics earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Spero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Q4 Earnings: $68.6M Loss, Pipeline Setbacks, and New Interim CEO Named - Stock Titan
A Glimpse of Spero Therapeutics's Earnings Potential - Benzinga
Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Spero Therapeutics Q4 Earnings: Rare Disease Pipeline and Financial Results Coming March 27 - StockTitan
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - The AM Reporter
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com Australia
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Projected to Post Earnings on Wednesday - The AM Reporter
Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India
Spero Therapeutics Inc Azioni (SPRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):